Lastly, the above mentioned mutations in CARD11 and inactivating mutations in TNFAIP3, a negative NFκB regulator, were also found in DLBCL patients not responding to ibrutinib treatment (82). This evidence concerns the gene NFKB1 and diffuse large B-cell lymphoma.